Φορτώνει......
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
BACKGROUND: In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. (18)F-labeled 2-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mut...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Imaging |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4331835/ https://ncbi.nlm.nih.gov/pubmed/25609545 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40644-014-0030-0 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|